206 related articles for article (PubMed ID: 32193105)
1. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas.
Liu X; Chen F; Li W
Int Immunopharmacol; 2020 Jun; 83():106400. PubMed ID: 32193105
[TBL] [Abstract][Full Text] [Related]
2. Association of DOK3 and infiltrated tumor-associated macrophages with risk for the prognosis of Porphyromonas gingivalis-infected oral cancer: a 12-year data analysis of 200 patients from a tertiary teaching hospital, Urumqi, China.
Li C; Li M; Wei W; Wang Z; Yu J; Gong Z
BMC Cancer; 2024 Apr; 24(1):534. PubMed ID: 38671413
[TBL] [Abstract][Full Text] [Related]
3. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
4. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity.
Vidyarthi A; Agnihotri T; Khan N; Singh S; Tewari MK; Radotra BD; Chatterjee D; Agrewala JN
Cancer Immunol Immunother; 2019 Dec; 68(12):1995-2004. PubMed ID: 31690954
[TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
6. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
7. Elevated TUBA1A Might Indicate the Clinical Outcomes of Patients with Gastric Cancer, Being Associated with the Infiltration of Macrophages in the Tumor Immune Microenvironment.
Wang D; Jiao Z; Ji Y; Zhang S
J Gastrointestin Liver Dis; 2020 Dec; 29(4):509-522. PubMed ID: 33331338
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients.
Lim J; Kim MJ; Park Y; Ahn JW; Hwang SJ; Moon JS; Cho KG; Kwack K
Sci Rep; 2019 May; 9(1):7895. PubMed ID: 31133717
[TBL] [Abstract][Full Text] [Related]
10. IFI30 expression is an independent unfavourable prognostic factor in glioma.
Liu X; Song C; Yang S; Ji Q; Chen F; Li W
J Cell Mol Med; 2020 Nov; 24(21):12433-12443. PubMed ID: 32969157
[TBL] [Abstract][Full Text] [Related]
11. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response.
Sielska M; Przanowski P; Wylot B; Gabrusiewicz K; Maleszewska M; Kijewska M; Zawadzka M; Kucharska J; Vinnakota K; Kettenmann H; Kotulska K; Grajkowska W; Kaminska B
J Pathol; 2013 Jul; 230(3):310-21. PubMed ID: 23520016
[TBL] [Abstract][Full Text] [Related]
12. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
Front Immunol; 2020; 11():588552. PubMed ID: 33329573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Biomarker ZNF311 and Its Correlation With Tumor Progression and Immune Infiltrates in Glioma.
Ge X; Jiang S; Wang Z; Hu N; Jiang R; Cai Z; Wu B; Zhang Y; Gong P
World Neurosurg; 2021 Jul; 151():e37-e46. PubMed ID: 33746099
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
[TBL] [Abstract][Full Text] [Related]
15. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical significance of DOK3 in renal clear cell carcinoma.
Wang YF; Hu YQ; Hu YN; Bai YC; Wang H; Zhang Q
J Int Med Res; 2023 May; 51(5):3000605231174974. PubMed ID: 37235715
[TBL] [Abstract][Full Text] [Related]
17.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
18. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
19.
Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
Front Immunol; 2021; 12():659659. PubMed ID: 33936093
[TBL] [Abstract][Full Text] [Related]
20. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
